NCT00515866View on ClinicalTrials.gov

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

July 31, 2012

Conditions
Pancreatic Neoplasms
Interventions
DRUG

KU-0059436 (AZD2281)(PARP inhibitor)

oral

DRUG

Gemcitabine

intravenous injection

Trial Locations (4)

Unknown

Research Site, New York

Research Site, Nashville

Research Site, London

Research Site, Oxford

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY